JP7884072B2 - Vegf及びtie2を結合する融合タンパク質並びにその使用 - Google Patents

Vegf及びtie2を結合する融合タンパク質並びにその使用

Info

Publication number
JP7884072B2
JP7884072B2 JP2024542028A JP2024542028A JP7884072B2 JP 7884072 B2 JP7884072 B2 JP 7884072B2 JP 2024542028 A JP2024542028 A JP 2024542028A JP 2024542028 A JP2024542028 A JP 2024542028A JP 7884072 B2 JP7884072 B2 JP 7884072B2
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
fusion protein
tie2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024542028A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503704A (ja
JP2025503704A5 (cg-RX-API-DMAC7.html
Inventor
チュ,ミンキュン
キム,クワンス
ハン,サンヨル
ドゥロスト,フィリップ
Original Assignee
インゲニア・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インゲニア・セラピューティクス・インコーポレイテッド filed Critical インゲニア・セラピューティクス・インコーポレイテッド
Publication of JP2025503704A publication Critical patent/JP2025503704A/ja
Publication of JP2025503704A5 publication Critical patent/JP2025503704A5/ja
Application granted granted Critical
Publication of JP7884072B2 publication Critical patent/JP7884072B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024542028A 2022-01-13 2023-01-12 Vegf及びtie2を結合する融合タンパク質並びにその使用 Active JP7884072B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263299177P 2022-01-13 2022-01-13
US63/299,177 2022-01-13
US202263310359P 2022-02-15 2022-02-15
US63/310,359 2022-02-15
US202263335805P 2022-04-28 2022-04-28
US63/335,805 2022-04-28
PCT/US2023/060582 WO2023137395A1 (en) 2022-01-13 2023-01-12 Vegf and tie2-binding fusion protein and uses thereof

Publications (3)

Publication Number Publication Date
JP2025503704A JP2025503704A (ja) 2025-02-04
JP2025503704A5 JP2025503704A5 (cg-RX-API-DMAC7.html) 2025-05-02
JP7884072B2 true JP7884072B2 (ja) 2026-07-02

Family

ID=87279731

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542028A Active JP7884072B2 (ja) 2022-01-13 2023-01-12 Vegf及びtie2を結合する融合タンパク質並びにその使用

Country Status (16)

Country Link
US (1) US20230287109A1 (cg-RX-API-DMAC7.html)
EP (1) EP4463482A4 (cg-RX-API-DMAC7.html)
JP (1) JP7884072B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250005053A (cg-RX-API-DMAC7.html)
AU (1) AU2023206363A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242904A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024002106A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024010934A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240342A (cg-RX-API-DMAC7.html)
DO (1) DOP2024000136A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416581A (cg-RX-API-DMAC7.html)
IL (1) IL314219A (cg-RX-API-DMAC7.html)
JO (1) JOP20240158A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024008737A (cg-RX-API-DMAC7.html)
PE (1) PE20260003A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023137395A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250128899A (ko) * 2024-02-20 2025-08-28 주식회사 맵틱스 Tie2 및 VEGF에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도
WO2026036282A1 (en) * 2024-08-13 2026-02-19 Pentavision Biosciences Limited Multispecific fusion proteins targeting angiogenic factors
US20260226178A1 (en) * 2024-12-23 2026-08-06 Ingenia Therapeutics, Inc. Fusion Proteins Comprising a Tie2 Binding Domain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210155697A1 (en) 2019-11-21 2021-05-27 Unity Biotechnology, Inc. Antibodies directed to tie-2 and methods of use
JP2021526801A (ja) 2018-06-07 2021-10-11 インスティテュート・フォー・ベイシック・サイエンスInstitute For Basic Science 抗Tie2抗体およびその使用
JP2022502367A (ja) 2018-09-24 2022-01-11 エアーピオ ファーマシューティカルズ, インコーポレイテッド HPTP−β(VE−PTP)およびVEGFを標的にする多特異性抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3415533A1 (en) * 2011-08-19 2018-12-19 Regeneron Pharmaceuticals, Inc. Anti-tie2 antibodies uses thereof
JP2020501508A (ja) * 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
JP2021507723A (ja) * 2017-12-05 2021-02-25 ユニバーシティ オブ ワシントンUniversity of Washington 視細胞における治療遺伝子の機能的発現を増強するための組成物および方法
WO2019235856A1 (ko) * 2018-06-07 2019-12-12 기초과학연구원 Tie2에 결합하는 항체 및 이의 용도
JP2021529557A (ja) * 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. 抗腫瘍免疫チェックポイント調節因子アンタゴニスト
JP7249060B2 (ja) * 2018-08-17 2023-03-30 トリカン・バイオテクノロジー・カンパニー・リミテッド 抗血管新生融合タンパク質およびその使用
CA3169967A1 (en) * 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021526801A (ja) 2018-06-07 2021-10-11 インスティテュート・フォー・ベイシック・サイエンスInstitute For Basic Science 抗Tie2抗体およびその使用
JP2022502367A (ja) 2018-09-24 2022-01-11 エアーピオ ファーマシューティカルズ, インコーポレイテッド HPTP−β(VE−PTP)およびVEGFを標的にする多特異性抗体
US20210155697A1 (en) 2019-11-21 2021-05-27 Unity Biotechnology, Inc. Antibodies directed to tie-2 and methods of use

Also Published As

Publication number Publication date
IL314219A (en) 2024-09-01
KR20250005053A (ko) 2025-01-09
GEAP202416581A (en) 2024-12-10
WO2023137395A1 (en) 2023-07-20
DOP2024000136A (es) 2024-10-15
AU2023206363A1 (en) 2024-08-15
CL2025002473A1 (es) 2025-11-14
MX2024008737A (es) 2024-09-11
US20230287109A1 (en) 2023-09-14
JOP20240158A1 (ar) 2024-07-14
CA3242904A1 (en) 2025-03-14
JP2025503704A (ja) 2025-02-04
EP4463482A1 (en) 2024-11-20
CL2024002106A1 (es) 2025-03-28
EP4463482A4 (en) 2026-05-06
CR20240342A (es) 2024-09-18
PE20260003A1 (es) 2026-01-06
CO2024010934A2 (es) 2024-10-31

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250423

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260616

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260622

R150 Certificate of patent or registration of utility model

Ref document number: 7884072

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150